N/A N=23 Treatment of Keratosis Pilaris With 810 nm Diode Laser
Keratosis Pilaris (KP)
Primary: Difference in Disease Severity Scores — 4; 3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 2 N=24 Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
N/A N=58 Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
Lesion Skin · Seborrheic Keratosis
Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
N/A N=25 Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
N/A N=11 Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy
Acne Keloidalis Nuchae
Primary: Percentage Change in Total AKN Lesions From Baseline to Week 16. — 49 percentage of lesion count reduction
N/A N=110 Skin Prick Test of KeraStat® Cream
Hypersensitivity
Primary: Reaction to Test Article — 0; 0.32; 0.23; 6.73 mm
Phase 3 N=490 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants
Phase 2 N=14 Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI
Phase 2 N=168 Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
Phase 3 N=479 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Actinic Keratoses
Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants
Phase 2 N=16 A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Actinic Keratosis
Primary: Maximum Observed Concentration (Cmax) for Ingenol Mebutate and Its Two Acyl Isomers (PEP015 and PEP025) Levels — NA; NA ng/mL
N/A N=29 Pre-Shave Gel and Brush in Pseudofolliculitis Barbae
Pseudofolliculitis Barbae
Primary: Patient Global Severity Assessment- Mechanics of Shaving — 12.9; 12.4; 8.5; 9.7 score on a scale
Phase 2 N=274 Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
Actinic Keratosis
Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields
N/A N=72 Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Skin Lesion · Skin Abnormalities · Sebaceous Hyperplasia
Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions
Phase 2 N=70 Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
Keratosis, Actinic
Primary: Lesion Clearance Rate — 88.7; 70.0; 16.7; 5.6 percentage of lesions cleared
Phase 2 N=12 Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Clinical Improvement in PRP Severity and Body Surface Area — 15.2 units on a scale — p=<0.001
Phase 4 N=551 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Keratosis
Primary: Number of Participants Who Experienced an Adverse Event — 472 participants
Phase 1 N=24 PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Actinic Keratosis
Primary: Change in Degree of Infiltration — 1.42 percentage change
Phase 3 N=450 Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation — 43; 9; 25; 5 participants — p=0.001
N/A N=20 Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Actinic Keratoses
Primary: Efficacy of Tixel for Treatment of Actinic Keratosis — -90.4 percentage change
Phase 2 N=75 Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Actinic Keratosis
Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions
N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
N/A N=25 KeraStat(R) Cream for Radiation Dermatitis
Radiation Dermatitis
Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale
Phase 3 N=255 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Patients With Complete Clearance of Actinic Keratosis (AKs) — 35; 6 Participants — p=<0.0001
Phase 1 N=31 DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone
Actinic Porokeratosis
Primary: Measurement of Treatment Efficacy Determined by DSAP-GASI Score (Disseminated Actinic Porokeratosis General Assessment Severity Index) — 50.0; 51.4 Percent decrease in…
Phase 3 N=203 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions — 42; 5 participants — p=0.001
Phase 3 N=269 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Actinic Keratosis
Primary: Complete Clearance Rate — 42; 17 participants — p=0.0001